Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Ophthalmology · Acanthamoeba Keratitis

The Road to Recovery: Standard Treatment for AK

At a Glance

Acanthamoeba keratitis is treated with intensive antiseptic eye drops like PHMB or chlorhexidine, initially requiring hourly application around the clock. Recovery is a marathon lasting six months to over a year, and treatment must not be stopped early to prevent dormant cysts from relapsing.

Treating Acanthamoeba keratitis (AK) is widely considered one of the most challenging tasks in ophthalmology. Because the organism can hide in its armored “cyst” form, the treatment is often intensive, long-term, and requires a high level of commitment from the patient [1][2].

The Front-Line Attack: Biguanides

The primary weapons against AK are a class of antiseptics called biguanides. These drops are designed to break through the amoeba’s defenses.

  • PHMB and Chlorhexidine: These are the two most common first-line medications [3]. Your doctor may prescribe Polyhexamethylene biguanide (PHMB) or chlorhexidine, usually at a concentration of 0.02% or 0.08% [3][4].
  • The Hourly Regimen: In the first 48 to 72 hours, these drops are often administered every hour, around the clock [1]. This “loading phase” is critical to saturate the corneal tissue and kill as many active trophozoites as possible before they can encyst [1][3].
  • Combination Therapy: Sometimes, a second type of drop called a diamidine (like propamidine or hexamidine) is added to provide a multi-pronged attack [3][5].

Helping the Drops Work: Debridement

Because the cornea is a natural barrier, it can be difficult for eye drops to reach amoebas that have burrowed deep into the tissue.

  • Epithelial Debridement: Your doctor may perform a procedure to gently remove the epithelium (the outermost layer of the cornea) [6].
  • Why it’s done: Removing this thin layer “opens the door” for the medication, allowing it to penetrate much deeper and more effectively into the area where the infection is most active [7][6]. It can also physically remove a large number of organisms from the eye’s surface [8].

Managing Stubborn Cases: Miltefosine

If the infection does not respond to standard drops, or if it has moved deep into the corneal structure, your doctor might introduce oral miltefosine [9][10].

  • How it helps: Miltefosine is a systemic medication that has shown the ability to kill both the active and dormant forms of the parasite in laboratory studies [11][12].
  • The Trade-off: While effective, it can cause gastrointestinal side effects like nausea or diarrhea and requires careful monitoring of your bloodwork [13][14].

The Danger of “The Steroid Trap”

It is tempting to use corticosteroids (steroid drops) to reduce the intense pain and redness associated with AK. However, using steroids too early—especially before the infection is fully controlled by anti-amoebic drops—is extremely dangerous [15].

Steroids suppress the local immune system, which can allow the amoeba to multiply and invade deeper layers of the eye even more rapidly [16][17]. Most experts recommend avoiding steroids entirely in the early stages, or using them only at very low doses later in treatment to manage inflammation once the infection is clearly responding to medication [16].

The Marathon Timeline

You should prepare for a treatment course that lasts anywhere from 6 months to over a year [1][18]. Even after the eye looks healthy and the pain is gone, the “cyst” form of the organism may still be present. Stopping the drops too early can lead to a relapse, where the dormant cysts “wake up” and restart the infection [2]. Success requires finishing the entire course as prescribed, even when you feel significantly better [1].

Common questions in this guide

What eye drops are used to treat Acanthamoeba keratitis?
The most common first-line medications are biguanide antiseptics like PHMB and chlorhexidine. In the first 48 to 72 hours, these eye drops must be applied every hour around the clock to aggressively attack the infection.
Why might my eye doctor scrape my eye surface?
Epithelial debridement is a procedure that gently removes the outermost layer of the cornea. This helps the medicated eye drops penetrate deeper into the eye where the amoebas are hiding and physically removes some of the organisms.
When is oral miltefosine used for eye infections?
Miltefosine is an oral pill that may be prescribed if the amoeba infection does not respond to standard eye drops or has burrowed deep into the eye. It can kill both active and dormant amoebas but requires careful monitoring due to potential side effects like nausea.
Are steroid eye drops safe to use for Acanthamoeba keratitis?
Using steroid eye drops too early can be extremely dangerous for this condition. Steroids suppress the eye's local immune system, which can allow the amoeba infection to multiply rapidly and spread deeper into the cornea.
How long does it take to cure Acanthamoeba keratitis?
Treatment is a marathon that typically lasts from six months to over a year. Even when your eye looks healthy and the pain is gone, dormant amoeba cysts can remain, so you must finish the entire course of drops to prevent the infection from returning.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What concentration of PHMB (0.02% or 0.08%) are we starting with, and what is the hourly schedule for the first few days?
  2. 2.If we need to perform epithelial debridement to help the drops penetrate, how often might that need to be repeated?
  3. 3.Under what specific clinical conditions would you consider adding oral miltefosine to my treatment plan?
  4. 4.How will we monitor for 'toxic keratopathy' or surface damage caused by the drops themselves during this long process?
  5. 5.What is our strict criteria for when it would be safe (or necessary) to introduce a low-dose steroid drop?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Acanthamoeba Keratitis: Perspectives for Patients.

    Bonini S, Di Zazzo A, Varacalli G, Coassin M

    Current eye research 2021; (46(6)):771-776 doi:10.1080/02713683.2020.1846753.

    PMID: 33151784
  2. 2

    Acanthamoeba Keratitis - A Case Report.

    Joshi LS, Gurung R

    Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH 2021; (13(25)):133-136 doi:10.3126/nepjoph.v13i1.29912.

    PMID: 33981107
  3. 3

    Acanthamoeba keratitis therapy: time to cure and visual outcome analysis for different antiamoebic therapies in 227 cases.

    Papa V, Rama P, Radford C, et al.

    The British journal of ophthalmology 2020; (104(4)):575-581 doi:10.1136/bjophthalmol-2019-314485.

    PMID: 31401556
  4. 4

    Polihexanide (PHMB) 0.08% versus currently used treatments for Acanthamoeba keratitis: indirect treatment comparisons.

    Papa V, Galeone C, De Francesco M, et al.

    BMJ open ophthalmology 2025; (10(1)) doi:10.1136/bmjophth-2024-002082.

    PMID: 40659372
  5. 5

    Topical Voriconazole as Supplemental Treatment for Acanthamoeba Keratitis.

    Musayeva A, Riedl JC, Schuster AK, et al.

    Cornea 2020; (39(8)):986-990 doi:10.1097/ICO.0000000000002315.

    PMID: 32243421
  6. 6

    Sandpaper curettage: A simple method to improve PDT outcomes for actinic keratosis.

    Heusinkveld LE, Bullock TA, Negrey J, et al.

    Photodiagnosis and photodynamic therapy 2022; (40()):103050 doi:10.1016/j.pdpdt.2022.103050.

    PMID: 35932960
  7. 7

    Photodynamic therapy combined with curettage for actinic keratosis on the face and scalp: An efficient treatment for field cancerization of the skin.

    Zhang C, Wang T, Lu W, et al.

    Photodiagnosis and photodynamic therapy 2025; (53()):104553 doi:10.1016/j.pdpdt.2025.104553.

    PMID: 40089170
  8. 8

    Acanthamoeba Keratitis Management and Prognostic Factors: A Systematic Review.

    Marques-Couto P, Monteiro M, Ferreira AM, et al.

    Journal of clinical medicine 2025; (14(7)) doi:10.3390/jcm14072528.

    PMID: 40217976
  9. 9

    Oral miltefosine for refractory Acanthamoeba keratitis.

    Hirabayashi KE, Lin CC, Ta CN

    American journal of ophthalmology case reports 2019; (16()):100555 doi:10.1016/j.ajoc.2019.100555.

    PMID: 31650083
  10. 10

    Oral Miltefosine as Adjunctive Treatment for Recalcitrant Acanthamoeba Keratitis.

    Dewan N, Ming W, Holland SP, et al.

    Cornea 2019; (38(7)):914-917 doi:10.1097/ICO.0000000000001968.

    PMID: 31170106
  11. 11

    In Vitro Efficacy of Miltefosine Against Clinical Isolates of Acanthamoeba spp. from Patients with Keratitis.

    Gowtham L, Sharma S, Bagga B

    Seminars in ophthalmology 2025; (40(8)):767-774 doi:10.1080/08820538.2025.2467272.

    PMID: 39998975
  12. 12

    Investigation of the in vitro cysticidal activity of miltefosine against Acanthamoeba spp.

    Chao M, Thongseesuksai T, Boonmars T, Laummaunwai P

    Journal of parasitic diseases : official organ of the Indian Society for Parasitology 2020; (44(2)):491-495 doi:10.1007/s12639-020-01204-w.

    PMID: 32508430
  13. 13

    Oral Miltefosine as Salvage Therapy for Refractory Acanthamoeba Keratitis.

    Thulasi P, Saeed HN, Rapuano CJ, et al.

    American journal of ophthalmology 2021; (223()):75-82 doi:10.1016/j.ajo.2020.09.048.

    PMID: 33045218
  14. 14

    Ophthalmic adverse effects of miltefosine in the treatment of leishmaniasis: a systematic review.

    Pal B, Atem TD, Kumari S, et al.

    Cutaneous and ocular toxicology 2024; (43(3)):190-197 doi:10.1080/15569527.2024.2380311.

    PMID: 39023122
  15. 15

    Topical Corticosteroids for Infectious Keratitis Before Culture-Proven Diagnosis.

    Hirano K, Tanaka H, Kato K, Araki-Sasaki K

    Clinical ophthalmology (Auckland, N.Z.) 2021; (15()):609-616 doi:10.2147/OPTH.S297202.

    PMID: 33623362
  16. 16

    Risk factors, management, and outcomes of Acanthamoeba keratitis: A retrospective analysis of 110 cases.

    Scruggs BA, Quist TS, Zimmerman MB, et al.

    American journal of ophthalmology case reports 2022; (25()):101372 doi:10.1016/j.ajoc.2022.101372.

    PMID: 35198803
  17. 17

    Topical corticosteroids in Acanthamoeba keratitis: Friend or foe?

    Wouters KA, Verhoekx JS, van Rooij J, et al.

    European journal of ophthalmology 2022; (32(1)):170-175 doi:10.1177/1120672120973606.

    PMID: 33183081
  18. 18

    Outcomes of amoebic, fungal, and bacterial keratitis: A retrospective cohort study.

    Moe CA, Lalitha P, Prajna NV, et al.

    PloS one 2022; (17(2)):e0264021 doi:10.1371/journal.pone.0264021.

    PMID: 35171970

This page explains standard treatment protocols for Acanthamoeba keratitis for educational purposes only. Always consult your ophthalmologist to determine the safest and most effective medication schedule for your specific eye infection.

Get notified when new evidence is published on Amoebic keratitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.